Lefkos Middleton

20.7k total citations · 3 hit papers
139 papers, 7.1k citations indexed

About

Lefkos Middleton is a scholar working on Molecular Biology, Neurology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Lefkos Middleton has authored 139 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Molecular Biology, 31 papers in Neurology and 28 papers in Cellular and Molecular Neuroscience. Recurrent topics in Lefkos Middleton's work include Dementia and Cognitive Impairment Research (22 papers), Parkinson's Disease Mechanisms and Treatments (21 papers) and Neurological diseases and metabolism (14 papers). Lefkos Middleton is often cited by papers focused on Dementia and Cognitive Impairment Research (22 papers), Parkinson's Disease Mechanisms and Treatments (21 papers) and Neurological diseases and metabolism (14 papers). Lefkos Middleton collaborates with scholars based in United Kingdom, United States and Cyprus. Lefkos Middleton's co-authors include Stanley B. Prusiner, Steve Gentleman, Abby Oehler, Joel C. Watts, Kurt Giles, Josip Car, Kyproula Christodoulou, Amanda L. Woerman, Chinedu Udeh‐Momoh and Jeffery M. Vance and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Lefkos Middleton

133 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism

2015 542 citations Stanley B. Prusiner, Amanda L. Woerman et al. Proceedings of the National Academy of Sciences profile →
Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990–2010: a systematic review and analysis

2013 537 citations Josip Car, Lefkos Middleton et al. The Lancet profile →
Associations of Social Isolation with Anxiety and Depression During the Early COVID-19 Pandemic: A Survey of Older Adults in London, UK

2020 294 citations Catherine Robb, Parthenia Giannakopoulou et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lefkos Middleton United Kingdom	41	2.4k	1.9k	1.6k	1.5k	1.2k	139	7.1k
Carlo Ferrarese Italy	46	2.0k 0.8×	2.1k 1.1×	1.8k 1.1×	1.4k 0.9×	1.1k 0.9×	302	6.7k
Michael Nilsson Australia	53	2.4k 1.0×	966 0.5×	2.3k 1.4×	1.6k 1.1×	2.6k 2.2×	238	11.1k
Alexis Elbaz France	58	1.6k 0.7×	3.2k 1.7×	1.4k 0.9×	2.3k 1.6×	942 0.8×	177	10.7k
James R. Burke United States	43	2.9k 1.2×	1.5k 0.8×	2.0k 1.2×	2.0k 1.3×	664 0.6×	130	8.8k
James C. Vickers Australia	51	2.1k 0.9×	1.2k 0.7×	2.3k 1.4×	2.1k 1.5×	1.1k 1.0×	255	7.7k
Tibor Hortobágyi Hungary	43	2.7k 1.1×	3.2k 1.7×	1.2k 0.7×	2.2k 1.5×	1.4k 1.2×	227	8.3k
Debby W. Tsuang United States	35	1.2k 0.5×	1.2k 0.6×	683 0.4×	2.2k 1.5×	681 0.6×	103	4.9k
Elan D. Louis United States	49	918 0.4×	4.1k 2.2×	1.5k 0.9×	1.1k 0.7×	610 0.5×	135	6.9k
Daniela Galimberti Italy	59	3.5k 1.4×	2.1k 1.1×	1.0k 0.6×	3.8k 2.6×	2.7k 2.3×	354	11.6k
Christopher M. Filley United States	42	1.5k 0.6×	1.3k 0.7×	840 0.5×	1.4k 0.9×	709 0.6×	153	6.7k

Countries citing papers authored by Lefkos Middleton

Since Specialization

Citations

This map shows the geographic impact of Lefkos Middleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lefkos Middleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lefkos Middleton more than expected).

Fields of papers citing papers by Lefkos Middleton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lefkos Middleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lefkos Middleton. The network helps show where Lefkos Middleton may publish in the future.

Co-authorship network of co-authors of Lefkos Middleton

This figure shows the co-authorship network connecting the top 25 collaborators of Lefkos Middleton. A scholar is included among the top collaborators of Lefkos Middleton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lefkos Middleton. Lefkos Middleton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Angioni, Davide, Lefkos Middleton, Randall J. Bateman, et al.. (2025). Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force. The Journal of Prevention of Alzheimer s Disease. 12(6). 100163–100163. 2 indexed citations

Kang, Sujin, Jamie Ford, Luc Bracoud, et al.. (2025). Prevalence and risk factors of cerebral microhemorrhages and superficial siderosis in cognitively unimpaired older adults: analysis from the CHARIOT‐PRO SubStudy. Alzheimer s & Dementia. 21(8). e70594–e70594.

Shi, Jiong, Lefkos Middleton, Merçé Boada, et al.. (2024). Now and future: Strategies for diagnosis, prevention and therapies for Alzheimer’s disease. Science Bulletin. 69(23). 3777–3784. 6 indexed citations

Zhao, Yujia, Karin Bröberg, Maria Kippler, et al.. (2023). Prediagnostic Blood Metal Levels and the Risk of Parkinson's Disease: A Large European Prospective Cohort. Movement Disorders. 38(12). 2302–2307. 4 indexed citations

Aune, Dagfinn, Sabrina Schlesinger, Yahya Mahamat‐Saleh, et al.. (2023). Diabetes mellitus, prediabetes and the risk of Parkinson’s disease: a systematic review and meta-analysis of 15 cohort studies with 29.9 million participants and 86,345 cases. European Journal of Epidemiology. 38(6). 591–604. 37 indexed citations

Dobričić, Valerija, Marcel Schilling, I Farkas, et al.. (2022). Common signatures of differential microRNA expression in Parkinson’s and Alzheimer’s disease brains. Brain Communications. 4(6). fcac274–fcac274. 13 indexed citations

Prusiner, Stanley B., Amanda L. Woerman, Daniel A. Mordes, et al.. (2015). Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proceedings of the National Academy of Sciences. 112(38). E5308–17. 542 indexed citations breakdown →

Larsen, Mark, et al.. (2015). Development of the CHARIOT Research Register for the Prevention of Alzheimer’s Dementia and Other Late Onset Neurodegenerative Diseases. PLoS ONE. 10(11). e0141806–e0141806. 14 indexed citations

Spencer, Jonathan P., Lefkos Middleton, & Ceri H. Davies. (2010). Investigation into the efficacy of the acetylcholinesterase inhibitor, donepezil, and novel procognitive agents to induce gamma oscillations in rat hippocampal slices. Neuropharmacology. 59(6). 437–443. 26 indexed citations

10.

Muglia, Pierandrea, Federica Tozzi, N. W. Galwey, et al.. (2008). Genome-wide association study of recurrent major depressive disorder in two European case–control cohorts. Molecular Psychiatry. 15(6). 589–601. 184 indexed citations

11.

Vilariño‐Güell, Carles, Alexandra I. Soto, Sarah Lincoln, et al.. (2008). ATP13A2variability in Parkinson disease. Human Mutation. 30(3). 406–410. 33 indexed citations

12.

Nicolaou, Paschalis, et al.. (2008). A novel c.5308_5311delGAGA mutation in Senataxin in a Cypriot family with an autosomal recessive cerebellar ataxia. BMC Medical Genetics. 9(1). 28–28. 25 indexed citations

13.

Yu, Yi, Diego F. Wyszynski, Dawn Waterworth, et al.. (2005). Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia. Journal of Lipid Research. 46(10). 2202–2213. 36 indexed citations

14.

Antonellis, Anthony, Rachel E. Ellsworth, Nyamkhishig Sambuughin, et al.. (2003). Glycyl tRNA Synthetase Mutations in Charcot-Marie-Tooth Disease Type 2D and Distal Spinal Muscular Atrophy Type V. The American Journal of Human Genetics. 72(5). 1293–1299. 420 indexed citations

15.

Middleton, Lefkos, Kyproula Christodoulou, Amar Mubaidin, et al.. (1999). Distal Hereditary Motor Neuronopathy of the Jerash Type. Annals of the New York Academy of Sciences. 883(1). 439–442. 10 indexed citations

16.

Drousiotou, Anthi, P.A. Ioannou, Georgios Christopoulos, et al.. (1998). Neonatal Screening for Duchenne Muscular Dystrophy: A Novel Semiquantitative Application of the Bioluminescence Test for Creatine Kinase in a Pilot National Program in Cyprus. Genetic Testing. 2(1). 55–60. 48 indexed citations

17.

Boteva, Kalina, et al.. (1994). Novel cystic fibrosis mutation associated with mild disease in Cypriot patients. Human Genetics. 93(5). 529–32. 2 indexed citations

18.

Othmane, Kamel Ben, Lefkos Middleton, Felicia Lennon, et al.. (1993). Localization of a Gene (CMT2A) for Autosomal Dominant Charcot-Marie-Tooth Disease Type 2 to Chromosome 1p and Evidence of Genetic Heterogeneity. Genomics. 17(2). 370–375. 120 indexed citations

19.

Schizas, Christos N., Constantinos S. Pattichis, Ian Schofield, P. Fawcett, & Lefkos Middleton. (1989). Artificial neural net algorithms in classifying electromyographic signals. 134–138. 5 indexed citations

20.

Holt, Ian, et al.. (1989). MOLECULAR GENETICS OF AMYLOID NEUROPATHY IN EUROPE. The Lancet. 333(8637). 524–526. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact